glp-1 agonist therapy glp-1_analogs [TUSOM How glucagon-like peptide 1 receptor

Additional launches are expected by the end of 2025, with the goal of reducing cost pressures on both employers and members

The American Association for the Study of Liver Diseases and the European Association for the Study of the Liver updated the terminology in 2023, renaming NAFLD as MASLD to better reflect the metabolic nature of the disease (Rinella et al., Hepatology 2023)

& Scarpa, S

As a matter of fact, taking into full account the intricacy of the numerous regulatory mechanisms involved in OS control as well as the complex interplay between the many events that contribute to the progressive degeneration and death of MNs, future neuroprotective pharmacological therapies will likely need to aim for an integrated treatment, acting on several levels to limit the progression of the disease

Novo Nordisk foundation, Boehringer Ingelheim